Conventional anticancer drug screening is typically performed in the absence of accessory cells of the tumor microenvironment, which can profoundly alter antitumor drug activity. To address this limitation, we developed the tumor cell-specific in vitro bioluminescence imaging (CS-BLI) assay. Tumor cells (for example, myeloma, leukemia and solid tumors) stably expressing luciferase are cultured with nonmalignant accessory cells (for example, stromal cells) for selective quantification of tumor cell viability, in presence versus absence of stromal cells or drug treatment. CS-BLI is high-throughput scalable and identifies stroma-induced chemoresistance in diverse malignancies, including imatinib resistance in leukemic cells. A stroma-induced signature in tumor cells correlates with adverse clinical prognosis and includes signatures for activated Akt, Ras, NF-B, HIF-1a, myc, hTERT and IRF4; for biological aggressiveness; and for self-renewal. Unlike conventional screening, CS-BLI can also identify agents with increased activity against tumor cells interacting with stroma. One such compound, reversine, shows more potent activity in an orthotopic model of diffuse myeloma bone lesions than in conventional subcutaneous xenografts. Use of CS-BLI, therefore, enables refined screening of candidate anticancer agents to enrich preclinical pipelines with potential therapeutics that overcome stroma-mediated drug resistance and can act in a synthetic lethal manner in the context of tumor-stroma interactions.
Tumor-stroma interactions are increasingly recognized as critical components of tumor biology 1 , including invasion and metastatic potential 2 . The interactions of bone marrow stromal cells (BMSCs) with tumor cells are important in tumor drug resistance 3, 4 through complex cytokine and adhesion-mediated mechanisms 3, 5 . Such microenvironment-mediated drug resistance accounts, at least in part, for the inability of conventional chemotherapies to cure such diseases as multiple myeloma (MM), the second most commonly diagnosed hematologic malignancy, as well as other disseminated neoplasias. Recently, FDA-approved novel agents including thalidomide, lenalidomide and bortezomib (PS-341) have been shown to overcome drug resistance mediated by BMSCs in preclinical models and to be clinically active even in cases of resistance to conventional chemotherapy [6] [7] [8] [9] [10] [11] .
Conventional in vitro assays used for high-throughput drug screening have limitations that prevent their use in co-culture settings. For example, conventional viability (such as MTT or Alamar blue) or cytotoxicity (such as lactate dehydrogenase release) assays do not distinguish normal from neoplastic cells, and the high background signal from stromal cells in co-cultures confounds quantification of tumor specific viability. In addition, assays that can distinguish tumor cells from accessory cells measure cell proliferation rather than viability ( 3 H-thymidine incorporation), require radioactivity (for example, 3 H-thymidine incorporation, chromium release assay) or involve laborious steps of limited high-throughput scalability (for example, flow cytometry).
To address these limitations, we developed the CS-BLI assay for the study of tumor-stroma cocultures. In these assays, malignant cells stably expressing luciferase (luc) are cultured with luc-negative stromal cells, and bioluminescent signal is proportional to the number of viable luc-expressing tumor cells. This allows for specific quantification of tumor cell viability in co-cultures with any luc-negative accessory cells of the tumor microenvironment. Using CS-BLI, we validated previous studies of stroma-induced drug resistance in MM, extended these studies to leukemia and solid tumors, and performed open-ended screening to identify new anticancer agents active in the context of tumor-stroma interactions. Specifically, we observed that dexamethasone and doxorubicin activity was lower when MM cells were cultured in the presence of stromal cells. In addition, imatinib and nilotinib activity was lower in certain leukemia cell lines when they interacted with stroma. CS-BLI is scalable to high-throughput application, which allows the study of tumor cell heterogeneity in terms of the cells' responses to stroma and various drugs. Using CS-BLI, we identified reversine, an agent with higher activity in the presence versus absence of stromal cells in vitro. Further testing of reversine in xenograft mouse models with subcutaneous versus diffuse tumors in bone provided results Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity concordant with our in vitro observations. CS-BLI, therefore, is a drug screening platform that takes into account tumor-microenvironmental interactions, thus providing a level of information that cannot be gained from conventional drug screening assays.
RESULTS

Stroma-induced proliferation and drug resistance of tumor cells
We plated luc-expressing MM.1S human multiple myeloma cells at increasing cell concentrations and increasing doses of luciferin substrate. The bioluminescent signal had a statistically significant linear correlation with the number of viable cells in each well for all luciferin concentrations tested, in both the presence and absence of HS-5 stromal cells (P < 0.001, R 2 ≥ 0.99, Supplementary Fig. 1 ). In the absence of stromal cells, the CS-BLI technique yielded results concordant with conventional techniques for evaluation of tumor cell viability (Supplementary Fig. 1 ), without requiring cell lysis. Culture of MM cells with BMSCs for 48 h at various stroma-tumor ratios distinguished cell lines with increased numbers of viable tumor cells (for example, MM.1S, MM.1R, KMS-18) from lines (for example, KMS-34, OPM-1) that did not show such a response ( Fig. 1) . Notably, proliferation of some cell lines was reduced in the presence of stroma ( Fig. 1a ), suggesting that stroma can have growth inhibitory effects in some settings.
We then compared the response of MM cells to various anticancer agents in the presence versus absence of stromal cells. Culture with BMSCs attenuated the responses of luc + MM.1S and MM.1R cells to dexamethasone and doxorubicin treatment ( Fig. 1b ; full dose-response curve shown in Supplementary Fig. 2a-d) , but not to bortezomib ( Fig. 2 ; full dose-response curve shown in Supplementary Fig. 2e,f) . Evaluation of drug-induced death of tumor cells in the context of tumor-stroma coculture using CS-BLI assay was consistent with flow cytometric analysis ( Supplementary Fig. 1e ).
We next expanded the application of CS-BLI co-culture testing to other classes of tumors and drugs. We tested antileukemia agents, including cytosine arabinoside (AraC), doxorubicin, imatinib and nilotinib, against luc-expressing Bcr-Abl + fusion protein K562 and KU812F leukemic cell lines in the presence versus absence of HS-5 stromal cells. The interaction with stromal cells attenuated the response of KU812F cells to AraC or to the Bcr-Abl inhibitors There is a significant difference in MM cell survival in the presence of stroma, which is attenuated by IL-6-blocking antibody (two-way ANOVA: drug P < 0.0001; antibody P < 0.0001; interaction P < 0.0001) and by the IL-6 receptor-blocking antibody (two-way ANOVA: drug P < 0.0001; antibody P < 0.0001; interaction P < 0.0001). Fig. 5 ).
imatinib and nilotinib, but not to doxorubicin ( Fig. 1b ; full doseresponse curve shown in Supplementary Fig. 3 ). In contrast, stromal cells protected K562 cells against low AraC dosages, but not against imatinib, nilotinib or doxorubicin at all dosages ( Fig. 1b ; full doseresponse curve shown in Supplementary Fig. 3 ). Culture with stromal cells modestly decreased response of the breast cancer cell line MDA-MB-231met to AraC; markedly decreased the sensitivity of A375 melanoma cells to AraC; and decreased the response of the anaplastic thyroid carcinoma cell line FRO to doxorubicin but not to AraC ( Fig. 1b ; full dose-response curves shown in Supplementary  Fig. 4 ). These data indicate that the microenvironmental effects of stromal cells can protect both hematological and solid tumors from various classes of anticancer drugs. We next assessed the protection conferred on MM cells against various drugs using co-cultures with different types of stromal cells, including stromal cell lines and primary stromal cells from individuals with MM. We observed doxorubicin resistance in MM.1S cells cultured with several BMSC lines (for example, KM101, KM103, KM104 and KM105 stromal lines; Fig. 1c ). In the presence versus absence of primary BMSCs from individuals with MM, the sensitivity of MM.1S and MM.1R cells to dexamethasone, doxorubicin and bortezomib ( Fig. 1c ; full dose-response curve shown in Supplementary Fig. 5 ) were consistent with results obtained with BMSC lines.
Mechanistic evaluation of stroma-mediated drug resistance
To further evaluate the mechanism of stroma-mediated drug resistance, we next probed the role of interleukin (IL)-6 signaling in the CS-BLI system. IL-6 is a principal cytokine secreted by stromal cells and a key regulator of MM growth and survival 3, 4 . MM-BMSC co-cultures were exposed to neutralizing antibodies to either IL-6 ( Fig. 2a ) or IL-6 receptor ( Fig. 2b) , both of which suppressed, but did not completely abrogate, stroma-induced resistance of MM.1S cells to doxorubicin. This observation suggested that other mechanisms in addition to IL-6 signaling contribute to stroma-mediated drug resistance.
To evaluate other potential mechanisms in an open-ended manner, we compared molecular profiles of GFP + MM cells in the absence versus presence of GFP − BMSCs to identify genes modulated by tumor-stroma interaction. We observed this interaction to trigger, in at least one of these cell lines, upregulation of transcripts ( Fig. 3 and Supplementary Table 1 ) for (i) cytokine and growth factors implicated in proliferation, survival and resistance of tumor cells to apoptosis, including IL6, members of the insulin-like growth factor signaling cascade 12 and members of the Notch pathway 13 ; (ii) oncogenic kinases (for example, PIM1, VAV1, VRK2 and SGK1), as well as Ras pathway members (for example, KRAS); (iii) other molecular targets functionally required for survival of oncogenically addicted MM and other tumor cells, including heat shock proteins (for example, different isoforms of hsp90, hsp70 and other heat shock proteins) and ubiquitin-proteasome pathway members (for example, several 26S-proteasome subunits, UBB, and ubiquitin-conjugating enzymes); (iv) transcription factors critical for tumor cells in general (for example, MYC and RELA) 14, 15 or MM cells in particular (for example, IRF4 and BCL6) 5,16,17 ; (v) regulators of chromatin remodeling, including histone deacetylases (for example, HDAC1 and HDAC8) that have emerged as therapeutic targets in MM and other neoplasias 18, 19 ; (vi) cell cycle regulators (for example, D-type cyclins, CDK1, CDK5, CDK6, BUB1 and BUB3), as well as AURKB 20 , and DNA repair enzymes (for example, TOP2A, TOP2B and ERCC1); (vii) caspase inhibitors (for example, CFLAR, BIRC3 and BIRC5) 15, 18, 21 ; antiapoptotic Bcl-2 family members (for example, MCL1) 22 ; and the mitochondrial regulators of cell viability VDAC1, VDAC2 and VDAC3, which have emerged as promising targets for therapy 23 ; (viii) extracellular matrix proteins and adhesion molecules; (ix) targets involved in remodeling of the microenvironment (for example, matrix metalloproteinases) or tumor cell responses to hypoxia (for example, HIF-1α-responsive genes); (x) regulators of angiogenesis (for example, IL8) 24 ; (xi) positive regulators of bone resorption in MM (for example, IL1B) 25 ; and (xii) chemokines (for example, CXCL1, CXCL2, CXCL3 and CXCL5) and chemokine receptors (for example, CXCR4) proposed to be involved in inflammatory responses, angiogenesis or chemotaxis of tumor cells to the bone milieu 26 . Immunoblotting analyses and transcription factor activity assays confirmed at protein and functional levels the upregulation of select molecules and pathways identified in our transcriptional profiling studies (data not shown).
To further evaluate how interaction with stromal cells modulates the activation status of different signaling pathways in MM cells, we studied the expression patterns of downstream target genes of these pathways. We observed significant increases in both ubiquitin-proteasome and ribosomal signatures; transcriptional signatures of Akt, NF-κB and Ras signaling activation ( Fig. 3b ; P < 0.05 for at least one cell line in each signature); transcriptional signatures of self renewal implicated in normal and cancer stem cell biology, such as myc 27, 28 , IRF4 (ref. 17), hTERT 29 , Hedgehog 30 and Notch 31 , as well as increased expression of genes upregulated in undifferentiated human embryonic stem cells 32 ; genes downregulated by p53 function 33 ; and a transcriptional signature previously reported to correlate with unfavorable clinical prognosis in MM 34 (Supplementary Fig. 6 for at least one cell line in each signature). These observations suggested that the transcriptional signature of MM cell response to stroma is enriched in genes that may correlate with clinical outcome. We therefore identified a transcriptional index of MM cell response to stroma (described in Supplementary Table 2 ) and applied this index to gene expression data from individuals with relapsed MM enrolled in a randomized clinical trial 11 comparing bortezomib to dexamethasone. High expression of stroma-responsive genes was associated with significantly shorter overall survival in dexamethasone-treated patients (P = 0.017, log-rank test, Fig. 3c ) but did not reach statistical significance in bortezomib-treated patients (P = 0.159, log-rank test, Fig. 3d ).
High-throughput CS-BLI screening
Our mechanistic observation that stroma-induced molecular changes in tumor cells correlate with clinical drug resistance led us to hypothesize that targeting those molecular pathways may sensitize tumors to drug treatment during interaction with stroma. To evaluate this concept and address the high-throughput scalability of CS-BLI, we screened antitumor activity of a total of over 3,000 compounds, including a library of bioactive compounds (Fig. 4a) and an 88-compound library of kinase inhibitors ( Table 1) . Specifically, we highlight results from three luc + cell lines (MM.1S, MM.1R and KU812F) screened in the presence and absence of stromal cells against a panel of documented kinase inhibitors ( Table 1) . We observed similar responses of MM.1S and MM.1R cells to compounds in the presence and absence of stromal cells to many agents (for example, BAY 11-7082); showed qualitative differences in KU812F response compared to MM cells (for example, piceatannol); and confirmed that more than half of compounds (including Ro 31-8220 and sphingosine) were less active in the presence than in the absence of stroma.
A small fraction of compounds were more active in the presence of stromal cells ( Table 1) . We also observed this pattern upon screening a library of known bioactive compounds (~1,000 different chemical entities) against luc + MM.1S cells (Fig. 4a) . Heterogeneity of tumor response in the context of the microenvironment can therefore be screened using the CS-BLI technique.
In vitro and in vivo antitumor activity of reversine
We extended the use of CS-BLI to testing of other compounds beyond those shown in Figure 4a . In the process of these tumor-stroma interaction studies, we identified 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) to be more active against tumor cells in the presence of stromal cells than in their absence (Fig. 4b) , and observed in an in vitro cell-free assay that this compound did not spuriously inhibit luc enzymatic activity (Supplementary Fig. 7a ). We then evaluated the in vivo activity of reversine (1 mg per kilogram body weight twice weekly) in a mouse subcutaneous tumor model, in which tumor cells do not interact with BMSCs, compared to a mouse model of diffuse tumor lesions in which tumor cells home to bone ( Fig. 4c-f) . We observed a significant decrease in tumor burden in the diffuse lesion model (Fig. 4c,e and Supplementary Fig. 8a ; two-way analysis of variance (ANOVA), P = 0.0003 for drug; P < 0.0001 for time; P < 0.0001 for the interaction), but not in the subcutaneous model (Fig. 4d,f and Supplementary Fig. 8b ; two-way ANOVA, P = 0.2486 for drug; P < 0.0001 for time; P = 0.5974 for the interaction). Mechanistically, the chemical similarity of reversine to ATP suggested that this agent may function as a kinase inhibitor. Indeed, in vitro kinase activity assays showed a distinct pattern of activity against kinases such as Auroras, JAK2 and SRC, with no activity against other kinases important for tumor cell survival, including AKT isoforms FGFR3 or GSK3 (Supplementary Fig. 7b ).
DISCUSSION
Conventional preclinical models in cancer drug discovery, including in vitro drug screens and in vivo subcutaneous xenograft models, do not take into account the tumor-stroma interactions that influence cancer pathophysiology. Consequently, the first exposure of a new drug to microenvironment-mediated resistance is in patients during clinical trials. To address this problem, which may contribute to the suboptimal translation of preclinical studies to clinical results, analysis of tumor-microenvironment interactions early in the drug development process is imperative. We therefore developed the in vitro CS-BLI, a high throughput-scalable strategy that quantifies the effect of anticancer agents on tumor cell viability in both the presence and the absence of non-neoplastic cells interacting with the tumor.
A notable strength of CS-BLI is its ability to identify how accessory cells modulate drug activity across different classes of tumor, accessory cell type and drug. In their microenvironment, tumor cells behave heterogeneously, with each particular response depending on the specific combination of tumor, accessory cell and drug evaluated. For instance, tumor cell lines with similar patterns of growth and drug response in the absence of stromal cells can have markedly divergent responses in the presence of stroma. The evaluation of all these variables requires the ability to screen the large number of permutations of them in a high-throughput manner. CS-BLI addresses this need and can conceivably be used to evaluate multiple cell types of the tumor milieu, modeling complex interactions between multiple cells, such as stromal cells, osteoclasts, osteoblasts and tumor cells of the bone or other relevant cell interactions in diverse neoplasias. The ability of stromal cells to modify drug-responsiveness of tumor cells is explained mechanistically, at least in part, by our molecular profiling studies. MM cells interacting with stroma show increased activation signatures for pathways associated with tumor cell proliferation, survival, drug resistance, and self renewal of stem cells. Examples include the Akt, Ras, NF-κB, HIF-1α, myc, hTERT, IRF4 and Notch pathways. The biological relevance of these pleiotropic molecular events is further supported by our observation that a distinct stromal-response signature correlates with adverse clinical prognosis in MM. This further supports the biological significance of stromamediated drug resistance, as highlighted in several large randomized clinical trials in MM 11, [35] [36] [37] that have shown that drugs with in vitro stroma-mediated drug resistance (for example, dexamethasone) have inferior clinical antitumor activity compared to drugs whose activity is not blocked by stromal cells (for example, bortezomib).
A distinctive advantage of CS-BLI is the identification of compounds more active in the presence than in the absence of stromal cells. Such drugs, which may target various signaling pathways triggered during tumor-stroma interaction, may have been missed using traditional screening methods that test only tumor cells in isolation. For example, the anti-MM activity of reversine is modest in the absence of stromal cells, but higher in their presence. Consistent with our in vitro observation, reversine remains more active in a model of diffuse MM bone lesions, which simulates the interaction of tumors with their microenvironment in individuals with MM, than in a subcutaneous tumor model lacking bone marrow stroma. This observation further supports the notion that preclinical models for testing of anticancer drugs should take into account the microenvironment with which tumor cells interact.
Our observation of stroma-induced sensitization to certain agents has many parallels to the traditional definition of synthetic lethality. Historically, the concept of synthetic lethality has focused on how tumor cells harboring specific constitutive oncogenetic lesions can be responsive to certain agents, whereas activity is not observed in the absence of these genetic events. Our study introduces the notion that a synthetic lethal phenotype, rather than being exclusively genotype dependent, can also be driven by the extrinsic influences of the tumor microenvironment. CS-BLI can probe both genetically and microenvironmentally determined synthetic lethality in a high-throughput scalable manner. This allows the testing of many permutations, including multiple candidate therapeutics, cell lines and nonmalignant accessory cells, thus enabling the previously intractable large-scale evaluation of how genetics and microenvironment interact to modulate cancer cell response to treatment.
Anticancer drug discovery is a serial process with high attrition at each step. Target identification, target validation, cell-based activity screens, toxicity screens and animal efficacy studies all eliminate drugs from the discovery pipeline. In contrast, CS-BLI can add to the pipeline those agents with enhanced antitumor activity in the context of tumor-microenvironment interactions. These agents are as yet eliminated from the process because conventional preclinical in vitro drug screens and in vivo subcutaneous xenograft studies do not take into account the importance of tumor-microenvironment interactions modulating in vivo response to therapy. By introducing the element of tumor-microenvironment interactions at earlier in vitro stages of drug development, CS-BLI allows the reprioritization of those drugs that are active in the tumor microenvironment and bridges the gap between the oversimplicity of conventional anticancer drug screening in monolayer cultures with the intractable complexity of in vivo studies in which tumor cells interact with their microenvironment.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
